When: 200 SMA test ($227.94) only on confirmed macro selloff with Polymarket recession probability >25%

Then: Re-enter at 33% of trimmed size

REDUCE

• Forward P/E of 21.3 (not 30x TTM) is reasonable for 25.7% ROE, $16.9B trailing FCF, and 64-year dividend growth streak
• Treasury yield comparison is a category error—JNJ investors buy yield plus capital appreciation plus defensive compounding, not yield alone
• Absence of retail chatter on a beta-0.23 defensive name is evidence of a different buyer base (pensions, insurers) that provides structural support at the 50 SMA of 250
• The 200 SMA at 227.94 has not been meaningfully tested in this advance—re-entry at 230-238 requires multiple favorable conditions simultaneously
• Trim of 25-40% with re-entry plan is too aggressive; instead trim 10-15% at 260-265, redeploy into cash or short-duration Treasuries, keep 85-90% intact
• MACD histogram at -0.28 with 3.33M shares volume resolves 60-70% of time as sideways-to-slightly-lower before trend resumption—this is a wait-and-see signal
• 10 EMA at 259.67 is immediate dynamic support; no technical basis for 30% trim until that breaks on heavy volume
• Seltorexant as 2027-2028 MDD asset supports premium multiple for structural investors; annualization of new $5.36 dividend run rate flows through income screens for 12 months

→ vs aggressive: TTM P/E of 30x is artificially inflated by Stelara biosimilar erosion and $865M Q4 2025 special charges crushing margins to 22.8%—forward P/E of 21.3 is the proper lens

→ vs aggressive: Direct yield comparison to 4%+ Treasury without adjusting for growth optionality, pipeline value, MedTech franchise, oncology portfolio, robotics platform, and non-US currency optionality is a category error

→ vs aggressive: Silence in a defensive blue-chip with 0.23 beta is the absence of noise consistent with the low-volatility regime holders purchased—this is a different buyer base, not a sentiment vacuum

→ vs aggressive: Re-entry framework at 230-238 requires ~12% drawdown, entry within tight 8-point band, and successful multi-tranche execution—prices overshoot to downside triggering stop cascades or bottom early and never revisit the zone

→ vs aggressive: If JNJ grinds sideways to 245 over six months because MACD divergence resolves bullishly and 50 SMA holds, trimming 30% at 262 permanently crystallizes tax event, gives up dividend payments, and earns nothing for patience

→ vs aggressive: Treating tactical consolidation (negative MACD histogram, modest volume) as regime change is the most common error a momentum trader can make on a structurally sound name

→ vs aggressive: ACCESS cardiac EP being 'modest' is fine—modest compounding in MedTech is the entire business model; using trader's time horizon to evaluate investor's asset on Seltorexant is inconsistent

→ vs neutral: HOLD doesn't incorporate real downside scenarios the trader's plan attempts to hedge against—conservative view requires acknowledging the re-entry timing risk even if rejecting the full trim

SELL (moderate trim of 15-20%)

• TTM P/E of 30.4 is the market's actual trading lens, not the forward 21.3; trailing multiples matter for institutional rebalancing and headlines
• MACD histogram at minus 0.28 while price is at highs is information, not noise; breakout on 3.33 million shares versus 6-8 million normal volume signals exhaustion, not confirmation
• Catalyst vacuum: Seltorexant is 2027-2028, ACCESS is distribution deal, Ottava is positioning not revenue, dividend hike was priced day of announcement
• Aggressive trim of 25-40% with re-entry at 230-238 targets roughly 25-30 point spread but poor probability weighting; 200 SMA at 227.94 has not been meaningfully tested in this advance
• Treasury yield comparison of 2.06% JNJ dividend to 4% Treasury is fundamentally flawed; income investors own JNJ for total return over multi-year horizon, not yield equivalent
• Conservative 10-15% trim is too small to materially change risk profile; essentially a placebo that doesn't redeploy capital with conviction
• Structural defensive bid (pensions/insurers, 50 SMA support) cushions drawdowns and accelerates recoveries but does not prevent them; JNJ traded at 172 twelve months ago, representing 35% drawdown from 262
• Q2 2026 fundamentals: revenue plus 6.6% YoY, gross margin 68.2%, FCF 7.3 billion, balance sheet deleveraged by 4.7 billion
• Polymarket data shows 86% probability of no Fed cuts in 2026, 8% recession odds; stable rate environment supports defensive income but doesn't justify aggressive trimming
• Sentiment score 6.3 out of 10 with low confidence (two of three sources unavailable); ambiguity favors moderate action rather than extremes
• Recommended trim: 15-20% at 260-265 capturing roughly 60-80% of technical premium without over-concentrating in either direction
• Redeploy trimmed capital into cash and short-duration Treasuries yielding 4-4.5%, providing real yield pickup and flexibility without forcing market timing decision
• Tighter trailing stop below 50 SMA at 247 or recent swing low at 247.02 rather than trader's 258 stop (too tight for structural holding)
• Conservative analyst's redeployment into cash/Treasuries has same timing problem in reverse; parking capital at 4% while JNJ never pulls back below 245 surrenders optionality

→ vs aggressive: The 25-40% trim with re-entry at 230-238 is operationally too rigid; requires 200 SMA test that has not occurred in entire advance and has poor probability weighting in 86% no-cut environment with low recession odds

→ vs aggressive: Treasury comparison of 2.06% JNJ dividend to 4% yield is flawed; strips out embedded growth optionality, pipeline value, MedTech franchise, currency exposure, and balance sheet

→ vs conservative: 10-15% trim is too small to meaningfully change risk profile; essentially a placebo that doesn't give enough capital to redeploy into asymmetric opportunities

→ vs conservative: Redeployment into cash/Treasuries avoids market timing problem by accepting lower expected return on redeployed capital; same problem in reverse as trimming

→ vs conservative: Conflating structural bid floor (50 SMA support, pension/insurer buying) with absence of cyclical drawdown risk; structural bid cushions and accelerates recovery but does not prevent drawdowns